☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
HER2-positive early breast cancer
Henlius Signs an Exclusive License Agreement with Accord for HLX02 (biosimilar- trastuzumab) in the US and Canada
October 1, 2020
Roche's Kadcyla (trastuzumab emtansine) Receives Health Canada's Approval for The Treatment of HER2-Positive Early Breast Cancer A...
November 29, 2019
Roche Reports Kadcyla (trastuzumab emtansine) vs Herceptin (trastuzumab) Achieve 1EP in P-III KATHERINE study
October 15, 2018
Load more...
Back to Home